Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Celsion Corp (CLSN)

Celsion Corp (CLSN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 19,768
  • Shares Outstanding, K 23,256
  • Annual Sales, $ 500 K
  • Annual Income, $ -11,880 K
  • 60-Month Beta 1.89
  • Price/Sales 41.86
  • Price/Cash Flow N/A
  • Price/Book 1.44
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.48
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 05/20/20
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/20
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.26
  • Growth Rate Est. (year over year) +384,330.77%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.6865 +25.30%
on 03/18/20
1.2000 -28.32%
on 03/06/20
-0.1798 (-17.29%)
since 02/28/20
3-Month
0.6865 +25.30%
on 03/18/20
1.7500 -50.85%
on 12/31/19
-0.7698 (-47.23%)
since 12/27/19
52-Week
0.6865 +25.30%
on 03/18/20
2.5300 -66.00%
on 04/05/19
-1.0998 (-56.11%)
since 03/29/19

Most Recent Stories

More News
Celsion Corp. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / March 26, 2020 / Celsion Corp. (NASDAQ:CLSN) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 26, 2020 at 11:00 AM Eastern...

CLSN : 0.8602 (+1.20%)
Celsion's OVATION 1 Study with GEN-1 in Ovarian Cancer Shows Strong Progression-Free Survival Treatment Effect Utilizing Medidata Synthetic Control Arm

Hazard Ratio of 0.53 for PFS in the Phase I Intent-To-Treat Population

CLSN : 0.8602 (+1.20%)
Celsion Corporation Reports 2019 Financial Results and Provides Business Update

Enters 2020 with a Strong Balance Sheet and an Advancing Clinical Pipeline

CLSN : 0.8602 (+1.20%)
Celsion's GEN-1 Immunotherapy Receives Orphan Drug Designation from the European Medicines Agency

Approval Adds 10 Years of Market Exclusivity Following Marketing Authorization in Europe

CLSN : 0.8602 (+1.20%)
Celsion Corporation to Hold Year-End 2019 Financial Results Conference Call on Thursday, March 26, 2020

Company to Provide Update on its Phase III OPTIMA Study in Primary Liver Cancer and its Phase I/II OVATION 2 Study in Ovarian Cancer

CLSN : 0.8602 (+1.20%)
Celsion Announces Highly Encouraging Initial Clinical Results from the Phase I Portion of the Phase I/II OVATION 2 Study with GEN-1 in Patients with Advanced Ovarian Cancer

R0 (Complete) Surgical Resection Rates for Patients Randomized to GEN-1 Treatment Arm Compare Favorably to Patients Receiving Neoadjuvant Chemotherapy Only

CLSN : 0.8602 (+1.20%)
Celsion CEO Issues Letter to Stockholders

Celsion Corporation (NASDAQ: CLSN), a leading oncology drug development company, announces that Michael H. Tardugno, the company's chairman, president and chief executive officer, issued the following...

CLSN : 0.8602 (+1.20%)
Celsion Corporation Prices $4.8 Million Registered Direct Offering

Celsion Corporation (NASDAQ: CLSN) ("Celsion" or the "Company"), today announced it has entered into securities purchase agreements with institutional investors for the purchase and sale of 4,571,428 shares...

CLSN : 0.8602 (+1.20%)
Celsion Corporation Announces DSMB has Confirmed Initial Safety of Weekly GEN-1 Dosing at 100 mg/m(2) in 15 Randomized Patients with Advanced Ovarian Cancer

Phase 2 Portion Will Continue After Patients Have Completed Their Full Treatment Regimen of up to 17 doses of GEN-1 plus Standard Chemotherapy

CLSN : 0.8602 (+1.20%)
Principal Investigator Professor Riccardo Lencioni Presents Celsion ThermoDox(R) Trial Data at SPECTRUM 2020 Interventional Oncology Conference

Company reaffirms its projection for second pre-planned interim efficacy analysis for Phase III OPTIMA Study in the second quarter of 2020

CLSN : 0.8602 (+1.20%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade CLSN with:

Business Summary

Celsion is dedicated to the development and commercialization of oncology drugs including tumor-targeting treatments using focused heat energy in combination with heat activated drug delivery systems. Celsion has research, license or commercialization agreements with leading institutions such as the...

See More

Key Turning Points

2nd Resistance Point 0.9934
1st Resistance Point 0.9268
Last Price 0.8602
1st Support Level 0.8168
2nd Support Level 0.7734

See More

52-Week High 2.5300
Fibonacci 61.8% 1.8258
Fibonacci 50% 1.6083
Fibonacci 38.2% 1.3907
Last Price 0.8602
52-Week Low 0.6865

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar